Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy

Area of Science:

• Biochemistry
• Endocrinology
• Pharmacology

Background:

• Hyperglycemia-induced vascular damage involves the hexosamine, advanced glycation end product (AGE), and diacylglycerol (DAG)-protein kinase C (PKC) pathways.
• These pathways are activated by increased glyceraldehyde-3-phosphate and fructose-6-phosphate availability.

Purpose of the Study:

• To investigate the potential of benfotiamine in inhibiting hyperglycemia-induced biochemical pathways and preventing diabetic vascular complications.
• To elucidate the mechanism by which benfotiamine exerts its effects.

Main Methods:

• Utilized animal models of diabetic retinopathy.
• Administered benfotiamine to assess its impact on key biochemical pathways and NF-kappaB activation.
• Measured the activity of transketolase and the levels of pathway metabolites.

Main Results:

• Benfotiamine inhibited the hexosamine, AGE, and DAG-PKC pathways by activating transketolase.
• Benfotiamine reduced hyperglycemia-associated NF-kappaB activation in diabetic animal retinas.
• Benfotiamine treatment prevented experimental diabetic retinopathy in animal models.

Conclusions:

• Benfotiamine demonstrates a multi-targeted inhibitory effect on pathways driving diabetic vascular damage.
• Activation of transketolase by benfotiamine is a key mechanism for its protective effects.
• Benfotiamine holds clinical promise for preventing and managing diabetic complications.